<DOC>
	<DOCNO>NCT00379795</DOCNO>
	<brief_summary>This open-label , multicenter , extension study intravitreally administer ranibizumab two cohort . The first cohort ( report ) enrol patient primary recurrent Choroidal Neovascularization ( CNV ) secondary Age-Related Macular Degeneration ( AMD ) complete treatment phase Genentech sponsor study ( FVF2598g ( NCT00056836 ) , FVF2587g ( NCT00061594 ) , FVF2428g ( NCT00056823 ) ) . The second cohort enrol patient macular edema secondary Retinal Vein Occlusion ( RVO ) complete 6-month treatment 6-month observation phase ( 12 month total ) Genentech sponsor study ( FVF4165g ( NCT00486018 ) FVF4166g ( NCT00485836 ) ) . The result second cohort report separately ( NCT01442064 ) . The first cohort study enrol two subset patient : ranibizumab experience ranibizumab-naive . Patients enrol within 14 day completion 24 month treatment phase previous study .</brief_summary>
	<brief_title>An Extension Study Evaluate Safety Tolerability Ranibizumab Subjects With Choroidal Neovascularization Secondary AMD Macular Edema Secondary RVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Signed informed consent form . Completion treatment phase ( Month 24 ) Genentechsponsored ranibizumab study AMD ( FVF2598g , FVF2587g , FVF2428g ) ( Cohort 1 ) Expectation investigator subject may potentially benefit intravitreal antivascular endothelial growth factor ( VEGF ) treatment Previous subfoveal focal laser photocoagulation study eye Previous pegaptanib sodium injection study eye Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within 1 month precede Day 0 extension study History submacular surgery surgical intervention AMD study eye History glaucoma filter surgery study eye History corneal transplant study eye Concurrent use systemic antiEGF agent Use AMD treatment approve FDA Use intravitreal Avastin ( R ) ( bevacizumab ) study eye and/or fellow eye CNV either eye due cause AMD , ocular histoplasmosis , trauma , pathologic myopia Cohort 1 History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye Uncontrolled glaucoma study eye ( defined intraocular pressure â‰¥ 30 mmHg despite treatment antiglaucoma medication ) Pregnancy lactation Premenopausal woman use adequate contraception History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Current treatment active systemic infection Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>CNV</keyword>
	<keyword>Lucentis</keyword>
	<keyword>AMD</keyword>
	<keyword>Age-related macular degeneration</keyword>
	<keyword>RVO</keyword>
</DOC>